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Pan drug-resistant Serratia marcescens: 
An emerging threat
To the Editor: The five most frequently reported organisms 
isolated from blood cultures worldwide are Klebsiella pneumoniae, 
Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa and 
Enterococcus species.[1,2] The emergence of carbapenem resistance 
has seriously compromised treatment options for organisms such 
as K. pneumoniae, E. coli and other Enterobacteriaceae such as 
Enterobacter species and Serratia marcescens. Colistin and tigecycline 
are last-resort therapeutic options for these carbapenem-resistant 
Enterobacteriaceae.[3] 
We have observed an increase in the number of carbapenem-
resistant S. marcescens isolates in blood cultures in our laboratory in 
the KwaZulu-Natal (KZN) region, South Africa, which is particularly 
worrisome, given that Serratia species are inherently resistant to 
colistin.
During 2017, S. marcescens was the 6th most common isolate in 
blood cultures. Of the 572 Enterobacteriaceae isolated from blood 
cultures, S. marcescens was the 3rd most common after E. coli and 
K. pneumo niae, accounting for 11% (63/572) of isolates. Ten S. marces­
cens isolates were carbapenem resistant; 7 of these were also resistant to 
tigecycline, thus making them pan drug resistant. All the carbapenem-
resistant S. marcescens isolates carried the New Delhi metallo-beta-
lactamase  1  (NDM­1) gene. Unlike other reports of S. marcescens 
bacteraemia, these isolates were from several different hospitals across 
KZN and were not linked to an outbreak.[4,5]
The emergence of pan drug-resistant S. marcescens in blood cultures 
in this region creates a challenge for the management of patients 
admitted to hospitals and intensive care units. Implementation of 
antimicrobial stewardship and strict infection control practices 
is imperative to prevent further dissemination of this formidable 
pathogen.
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